IRIS
DEL PRINCIPE, MARIA ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.613
EU - Europa 2.877
AS - Asia 800
SA - Sud America 31
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 12
AF - Africa 11
Totale 34.362
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.576
DE - Germania 644
IT - Italia 626
IE - Irlanda 485
CN - Cina 442
UA - Ucraina 427
GB - Regno Unito 197
KR - Corea 183
FR - Francia 124
FI - Finlandia 95
SE - Svezia 87
RU - Federazione Russa 74
CA - Canada 31
PL - Polonia 26
IN - India 25
BE - Belgio 22
NL - Olanda 22
JP - Giappone 17
AU - Australia 16
HK - Hong Kong 16
AT - Austria 14
IR - Iran 13
UZ - Uzbekistan 13
PH - Filippine 12
TH - Thailandia 12
BR - Brasile 11
SG - Singapore 11
VN - Vietnam 11
ES - Italia 10
TR - Turchia 8
EU - Europa 7
AR - Argentina 6
CL - Cile 6
MY - Malesia 6
SA - Arabia Saudita 6
A2 - ???statistics.table.value.countryCode.A2??? 5
MX - Messico 5
PE - Perù 5
TW - Taiwan 5
BD - Bangladesh 4
EG - Egitto 4
ID - Indonesia 4
IL - Israele 4
NO - Norvegia 4
HR - Croazia 3
PK - Pakistan 3
PT - Portogallo 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
CO - Colombia 2
GR - Grecia 2
MA - Marocco 2
NZ - Nuova Zelanda 2
QA - Qatar 2
ZA - Sudafrica 2
AL - Albania 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
EC - Ecuador 1
HU - Ungheria 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
SD - Sudan 1
SN - Senegal 1
TN - Tunisia 1
Totale 34.362
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.113
Wilmington 8.873
Houston 5.144
Fairfield 1.320
Chandler 975
Ann Arbor 731
Ashburn 670
Seattle 532
Cambridge 464
Dublin 405
Jacksonville 351
Dearborn 288
Medford 288
New York 268
Rome 241
Beijing 192
Lawrence 135
Zhengzhou 99
San Diego 71
Mülheim 52
Menlo Park 47
Creede 43
Milan 43
Engelhard 32
Seoul 28
Redwood City 26
Bologna 25
Center 24
London 24
Shanghai 23
Brussels 21
Palo Alto 21
Hefei 20
Norwalk 20
Toronto 19
University Park 17
Guangzhou 14
Nanjing 14
Falls Church 13
Kraków 13
Kunming 13
Santa Clara 12
Bang Bai Mai 11
Redmond 11
Kilburn 10
Lappeenranta 10
Saint Petersburg 10
Dong Ket 9
Nürnberg 9
Phoenix 9
Verona 9
Helsinki 8
Hounslow 8
Tokyo 8
Boardman 7
Chiswick 7
Groningen 7
Hangzhou 7
Innsbruck 7
Los Angeles 7
Mountain View 7
Pune 7
Roebling 7
Turin 7
Jinan 6
Kuala Lumpur 6
Renton 6
Bari 5
Diyarbakır 5
Islington 5
Lima 5
Mumbai 5
Nanchang 5
Naples 5
Padova 5
Prescot 5
São Paulo 5
Auburn Hills 4
Bari Sardo 4
Birmingham 4
Buenos Aires 4
Clearwater 4
Colorado Springs 4
Frankfurt am Main 4
Indiana 4
Jeddah 4
Manila 4
Melbourne 4
Montreal 4
New Bedfont 4
Rieti 4
San Francisco 4
San Mateo 4
Taichung 4
Warsaw 4
Washington 4
Altamura 3
Amsterdam 3
Ancona 3
Avesnes-le-sec 3
Totale 31.062
Salva come PNG Salva come JPEG
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 539
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 471
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 436
Clinical significance of CD38 expression in chronic lymphocytic leukemia 425
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 419
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 410
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 409
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 405
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 405
Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study 402
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 397
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports 391
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 389
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 380
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 380
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 379
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations 378
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 376
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 376
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 374
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 373
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 371
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 371
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 369
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 366
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells 363
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 363
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 362
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 361
A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia 360
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 354
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 353
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 353
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 350
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 348
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 347
Monitoring of minimal residual disease in acute myeloid leukemia 347
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 343
Circulating regulatory T cells in clinical monoclonal B-cell lymphocytosis. 341
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 341
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 340
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 339
Treatment of low-blast count AML using hypomethylating agents 339
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 334
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 333
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 333
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 331
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 330
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 329
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 329
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 329
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 327
Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia 325
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells 321
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 320
Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia [4] 319
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 318
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 316
Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia 314
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 314
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 313
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia 313
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 311
Thrombosis in adult patients with acute leukemia 310
Longitudinal detection of DNMT3AR882Htranscripts in patients with acute myeloid leukemia 308
Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration? 305
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 304
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. 302
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. 301
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 299
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis 299
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia 299
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias 297
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. 293
Risk allocation of adults patients with non-M3 acute myeloid leukemia 292
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy 291
Apoptosis and immaturity in acute myeloid leukemia 283
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient 282
Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? 280
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes 277
Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling 270
CD69 is independently prognostic in chronic lymphocytic leukemia: acomprehensive clinical and biological profiling study 270
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 260
In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab 259
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 252
The emerging role of measurable residual disease detection in AML in morphologic remission 243
FCγ chimeric receptor-engineered T cells: Methodology, advantages, limitations, and clinical relevance 239
Gemtuzumab ozogamicin in combination with intensive chemotherapy for relapsed/refractory acute myeloid leukemia 237
Fludarabine, Cytarabine and Gentuzumab Ozogamicin (FLA-GO) as Salvage Therapy and Bridge to Transplant in Adult Relapsed Acute Myeloid Leukemia (AML) Patients 231
Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 226
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse 218
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network 217
An evaluation of enasidenib for the treatment of acute myeloid leukemia 180
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 168
Rhodotorula infection in haematological patient: Risk factors and outcome 166
Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases 162
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 158
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 146
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 144
Applications and efficiency of flow cytometry for leukemia diagnostics 141
Totale 31.963
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.814
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.814
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.770 0 0 0 0 0 0 0 0 0 0 891 879
2019/20208.742 666 719 610 742 769 915 837 845 786 739 508 606
2020/20215.719 638 625 618 758 589 548 718 554 166 196 233 76
2021/20221.672 62 172 46 48 33 171 100 113 139 165 92 531
2022/20232.654 286 230 230 261 167 474 318 163 285 47 134 59
2023/2024986 104 52 138 36 99 338 57 83 43 32 4 0
Totale 35.003